Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.96 |
| ▸ | POLB | P06746 | 3/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | TERT | O14746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4410668 | 0.98 | MAPT (1.00) | MAPTPOLBHTTL3MBTL1KMT2A | |
| SCHEMBL4419502 | 0.91 | MAPT (0.80) | MAPTPOLBHTTL3MBTL1KMT2A | |
| SCHEMBL29714371 | 0.88 | MAPT (0.75) | MAPTPOLBHTTL3MBTL1KMT2A | |
| SCHEMBL9471513 | 0.83 | MAPT (0.69) | MAPTPOLBHTTL3MBTL1KMT2A | |
| SCHEMBL316264 | 0.82 | MAPT (0.67) | MAPTPOLBHTTKMT2ALMNA | |
| SCHEMBL15369925 | 0.79 | POLB (1.00) | MAPTPOLBHTTL3MBTL1KMT2A | |
| SCHEMBL5109896 | 0.78 | MAPT (0.62) | MAPTPOLBHTTL3MBTL1KMT2A | |
| SCHEMBL2825299 | 0.77 | MAPT (0.61) | MAPTPOLBHTTL3MBTL1KMT2A | |
| SCHEMBL8165558 | 0.77 | MAPT (0.66) | MAPTPOLBL3MBTL1KMT2AALDH1A1 | |
| SCHEMBL9579397 | 0.77 | MAPT (0.66) | MAPTPOLBL3MBTL1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11274102-B2 | Compounds useful in HIV therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-03-15 | — | — | US | disclosed |
| US-20200325147-A1 | Compounds Useful in HIV Therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-10-15 | — | — | US | disclosed |
| US-20200325147-A1 | Compounds Useful in HIV Therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-10-15 | — | — | US | disclosed |
| CN-103121996-A | Novel heteroaryl-substituted arylaminopyridine derivatives as mek inhibitors | SERONO LAB | 2013-05-29 | — | — | CN | disclosed |
| EP-2065383-A1 | Indazole compounds and methods of use thereof as protein kinase inhibitors | Signal Pharmaceuticals, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | BHAGWAT SHRIPAD S | 2009-04-16 | — | — | US | disclosed |
| EP-1692128-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS | Signal Pharmaceuticals LLC (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | BHAGWAT SHRIPAD S | 2006-01-05 | — | — | US | disclosed |
| WO-2005051942-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | WNT3, WNT3A, WNK3 | MAPT 1051/4885POLB 3400/4885HTT 1565/4885 |
| US-20200325147-A1 | Compounds Useful in HIV Therapy | CCR5, CD4, G6PD | MAPT 589/4885POLB 560/4885HTT 2725/4885 |
| US-11274102-B2 | Compounds useful in HIV therapy | CCR5, CD4, G6PD | MAPT 589/4885POLB 560/4885HTT 2725/4885 |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | WNT3, WNT3A, WNK3 | MAPT 1061/4885POLB 3558/4885HTT 1407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.